123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Phase 3

• Conditions: Pheochromocytoma; Paraganglioma; Neuroblastoma; Medullary Thyroid Carcinoma; Carcinoid Tumors

• Registration Number: NCT01373736
• Lead Sponsor: Vancouver Coastal Health

Brief Summary

The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.

Detailed Description

Not available

Study Timeline

• Status Verified: 2011-06
• Study First Submitted: 2011-06-13
• Study First Submitted QC: 2011-06-13
• Last Update Submitted: 2011-06-13
• Study First Posted: 2011-06-15
• Last Update Posted: 2011-06-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors;
• subjects must be able and willing to comply with study procedures.

Exclusion Criteria

• Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL [265 µmol/L]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake;
• Subjects unable to tolerate lying supine;
• Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Vancouver Coastal Health; 🇨🇦 Vancouver, British Columbia, Canada